EU Inspectors to Focus on Integrity of Process Validation Data
This article was originally published in The Gold Sheet
Executive Summary
The revised Annex 15 is prompting EU inspectors to take a new look at data integrity problems. One EU inspector warns industry to be vigilant in looking for such problems in validation reports, and shares some news about Europe’s three-batch minimum for process validation.
You may also be interested in...
Industry Urges EU to Align Draft Validation Guidance with ICH and FDA
European pharmaceutical manufacturers say that the European Union’s draft process validation guidance should be better aligned with the International Conference on Harmonization and FDA lifecycle approaches to process validation and that major changes are needed before it is a workable guideline. EMA issues two concept papers to revise Annex 15 and Annex 17 to reflect lifecycle approaches.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.